

To: [REDACTED] [REDACTED] [REDACTED]@minvws.nl]; [REDACTED] [REDACTED] [REDACTED]@modernatx.com]
Cc: [REDACTED] [REDACTED] [REDACTED]@modernatx.com]
From: [REDACTED] [REDACTED]
Sent: Mon 1/4/2021 10:22:14 PM
Subject: RE: Moderna Invoice for December Option Increase - Reissued
Received: Mon 1/4/2021 10:22:52 PM

Hi [REDACTED]

Happy New Year! Hope this email finds you well! To clarify, yes the invoice provided is only for the additional option doses. An invoice will be provided for the regular initial doses based on the following schedule:

-40% of the number of initial doses ordered by respective member state multiplied by price in euros based on the [REDACTED] payable within thirty (30) days after the receipt of Marketing Authorization for the Product
 -40% of the number of initial doses delivered to respective member state multiplied by price in euros based on [REDACTED] payable within thirty (30) days after receipt of the Moderna invoice for each delivery

In terms of the delivery schedule, this will be communicated once finalized.

Thanks!

[REDACTED] [REDACTED]
 [REDACTED] Revenue and Collaboration | Moderna, Inc.
 [REDACTED] [@modernatx.com](mailto:[REDACTED]@modernatx.com) | modernatx.com
 mobile [REDACTED] [REDACTED]



Please consider the environment before printing this email

Confidentiality notice and disclaimer: The information in this message and any attachments is intended for the exclusive use of the addressee(s), is confidential and may be privileged or otherwise protected from disclosure. Any review, retransmission, dissemination or other use of, or taking of any action in reliance upon, of any such information by persons or entities other than the intended addressee(s) is prohibited. If you have received this message in error and are not the intended addressee, please notify the sender immediately and delete this message and any attachments from your system without reading or disclosing them. If you are not the intended addressee, be advised that any use of the information in this message and any attachment is prohibited and may be unlawful, and you must not copy this message or attachment or disclose the contents to any other person.

From: [REDACTED] [REDACTED] <[REDACTED]@minvws.nl>
Sent: Thursday, December 31, 2020 3:03 AM
To: [REDACTED] [REDACTED] <[REDACTED]@modernatx.com>
Cc: [REDACTED] [REDACTED] <[REDACTED]@modernatx.com>; [REDACTED] [REDACTED] <[REDACTED]@modernatx.com>
Subject: RE: Moderna Invoice for December Option Increase - Reissued

EXTERNAL

Dear [REDACTED]

Thank you for your mail.

Do I understand it correctly that this invoice is only for the options?

Do we get a separate one for the regular doses?

And do you know when we will receive clarity about the delivery scheme?

Best regards,

[REDACTED] [REDACTED]

Verzonden met BlackBerry Work
www.blackberry.com

Van: [REDACTED] [REDACTED] <[REDACTED]@modernatx.com<[REDACTED]@modernatx.com>>

Datum: donderdag 31 dec. 2020 1:05 AM

Aan: [REDACTED] [REDACTED] <[REDACTED]@minvws.nl<[REDACTED]@minvws.nl>>

Kopie: [REDACTED] [REDACTED] <[REDACTED]@modernatx.com<[REDACTED]@modernatx.com>>, [REDACTED] [REDACTED]
<[REDACTED]@modernatx.com<[REDACTED]@modernatx.com>>

Onderwerp: Moderna Invoice for December Option Increase - Reissued

Hi [REDACTED]

Please disregard the previous email. Attached you can find the reissued Moderna invoice for Moderna's December Option increase payment under contract no. [REDACTED]

Best regards,

[REDACTED] [REDACTED]

[REDACTED]

Revenue and R&D Collaboration

office (617) 460-4276 | modernatx.com

[signature_2127785708]<<http://www.modernatx.com/>>

[signature_1146048737]<<http://facebook.com/modernatx/>> [signature_118176511] <https://twitter.com/moderna_tx>

[signature_1781966198] <<http://youtube.com/user/ModernaTx>> [signature_1489564253]

<<https://linkedin.com/company/moderna->>

P Please consider the environment before printing this email

Confidentiality notice and disclaimer: The information in this message and any attachments is intended for the exclusive use of the addressee(s), is confidential and may be privileged or otherwise protected from disclosure. Any review, retransmission, dissemination or other use of, or taking of any action in reliance upon, of any such information by persons or entities other than the intended addressee(s) is prohibited. If you have received this message in error and are not the intended addressee, please notify the sender immediately and delete this message and any attachments from your system without reading or disclosing them. If you are not the intended addressee, be advised that any use of the information in this message and any attachment is prohibited and may be unlawful, and you must not copy this message or attachment or disclose the contents to any other person.